Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645409 | 0.89 | PDE2A (0.44) | PDE2APPARGNPSR1TAS1R3TAS1R1 | |
| SCHEMBL10271858 | 0.86 | PDE2A (0.46) | PDE2APPARGMEN1KMT2AMAPT | |
| SCHEMBL1643884 | 0.85 | PDE2A (0.49) | PDE2A | |
| SCHEMBL1645545 | 0.83 | PDE2A (0.42) | PDE2APPARGNPSR1CYP3A4 | |
| SCHEMBL1643305 | 0.82 | CCR1 (0.41) | PDE2APPARGAKT1MEN1KMT2A | |
| SCHEMBL1644460 | 0.82 | NR1H4 (0.38) | PDE2APPARGMAPTCYP3A4 | |
| SCHEMBL1644853 | 0.81 | PDE2A (0.43) | PDE2AAKT1NPSR1CYP3A4TAS1R3 | |
| SCHEMBL1645337 | 0.77 | PDE2A (0.42) | PDE2A | |
| SCHEMBL1754353 | 0.76 | KMT2A (0.44) | PDE2APPARGMEN1KMT2ACYP3A4 | |
| SCHEMBL2361366 | 0.76 | KMT2A (0.44) | PDE2APPARGMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | PDE2A 1116/4885PPARG 376/4885MRGPRX4 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.